This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Acasti Pharma Crecimiento futuro
Future controles de criterios 4/6
Información clave
-28.1%
Tasa de crecimiento de los beneficios
-30.2%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 75.3% |
| Tasa de crecimiento de los ingresos | 26.1% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 16 Feb 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2025 | 97 | -38 | 27 | N/A | 3 |
| 3/31/2024 | 160 | 161 | 12 | -25 | 2 |
| 3/31/2023 | N/A | -6 | -17 | -17 | 2 |
| 12/31/2022 | N/A | -17 | -16 | -16 | N/A |
| 9/30/2022 | N/A | -17 | -17 | -17 | N/A |
| 6/30/2022 | N/A | -11 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -10 | -17 | -17 | N/A |
| 12/31/2021 | 0 | -12 | -16 | -16 | N/A |
| 9/30/2021 | 0 | -11 | -15 | -15 | N/A |
| 6/30/2021 | 0 | -18 | -14 | -14 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -14 | N/A |
| 12/31/2020 | 0 | 3 | -16 | -15 | N/A |
| 9/30/2020 | N/A | -6 | -19 | -18 | N/A |
| 6/30/2020 | N/A | -21 | -21 | -20 | N/A |
| 3/31/2020 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2019 | N/A | -56 | -29 | -29 | N/A |
| 9/30/2019 | N/A | -46 | -29 | -29 | N/A |
| 6/30/2019 | N/A | -42 | -27 | -27 | N/A |
| 3/31/2019 | N/A | -39 | -25 | -25 | N/A |
| 12/31/2018 | N/A | -31 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -34 | -17 | -16 | N/A |
| 6/30/2018 | N/A | -20 | -13 | -13 | N/A |
| 3/31/2018 | N/A | -17 | -10 | -10 | N/A |
| 3/31/2017 | N/A | -8 | -7 | -5 | N/A |
| 11/30/2016 | 0 | -7 | N/A | -5 | N/A |
| 8/31/2016 | 0 | -7 | N/A | -5 | N/A |
| 5/31/2016 | 0 | -6 | N/A | -6 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: ACST's earnings are forecast to decline over the next 3 years (-28.1% per year).
Beneficios vs. Mercado: ACST is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: ACST is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: ACST's revenue (26.1% per year) is forecast to grow faster than the Canadian market (5.5% per year).
Ingresos de alto crecimiento: ACST's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time